DelveInsight’s “Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Type 2 Diabetes Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Type 2 Diabetes therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Type 2 Diabetes treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market. 

Type 2 Diabetes: An Overview

Diabetes is a chronic metabolic condition characterized by high or low blood glucose (or blood sugar) levels, leading to significant damage to the heart, blood vessels, eyes, kidneys, and nerves over time. The rationale behind developing diabetes incorporates two factors: insufficient insulin production (produced by the pancreas and reduced blood glucose) or unsatisfactory cell response to insulin action.

Clinically, diabetes is classified into three types, type 1 diabetes (TD-1), type 2 diabetes (TD2), and gestation diabetes. Type 2 diabetes, the most common type of diabetes, is a disease that occurs when the blood glucose, also called blood sugar, is too high. People who are middle-aged or older are most likely to get this kind of diabetes. It used to be called adult-onset diabetes. But type 2 diabetes also affects kids and teens, mainly because of childhood obesity.

Focusing on the chronic and severe nature of TD1 and TD2, the treatment approach for them is quite comprehensive; regularization of glucose metabolism and control of risk factors ( e.g., arterial hypertension) is the key treatment target for type 2 diabetes.

Type 2 Diabetes Market Key Facts

• More than 34 million Americans have diabetes (about 1 in 10), and approximately 90-95% of them have type 2 diabetes. Type 2 diabetes most often develops in people over age 45, but more and more children, teens, and young adults are also developing it (Centers for Disease Control and Prevention, n.d.).

• Type 2 diabetes is, by far, the most prevalent form of diabetes. In the UK, type 2 diabetes accounts for about 90% of all diabetes cases. The risk of developing type 2 diabetes through family genes is much higher. Recently published information, based on data from the Health Survey for England, estimates that 10.7 percent of the English population (approximately 5 million people) are at increased risk of Type 2 diabetes with an HbA1c between 42-46 mmol/mol (6.0-6.4) (Diabetes UK, n.d.).

Type 2 Diabetes Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Type 2 Diabetes therapies in the market. It also provides a detailed assessment of the Type 2 Diabetes market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Type 2 Diabetes drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Type 2 Diabetes Epidemiology

The epidemiology section covers detailed insights into the historical, and current Type 2 Diabetes patient pool and forecasted epidemiology trends for every seven major countries (7MM)  from 2019 to 2032.

The Report Covers the Type 2 Diabetes Epidemiology Segmented as-

• Total Prevalent Cases of Type 2 Diabetes in 7MM [2019–2032]

• Treated cases of Type 2 Diabetes in the 7MM [2019–2032]

• Total diagnosed prevalent cases of Type 2 diabetes in the 7MM [2019–2032]

• Total age-specific prevalent diagnosed cases of Type 2 Diabetes in the 7MM [2019 –2032]

• Total gender-specific prevalent diagnosed cases of Type 2 Diabetes in the7MM [2019–2032]

Type 2 Diabetes Drugs Uptake and Pipeline Development Activities

The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Type 2 Diabetes market or expected to be launched during the study period. The analysis covers the market share by Type 2 Diabetes drugs, patient uptake by therapies, and sales of each drug. 

The report’s drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Type 2 Diabetes Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @ 

https://www.delveinsight.com/sample-request/type-2-diabetes-market

Type 2 Diabetes Therapeutics Assessment

The Type 2 Diabetes market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and increased healthcare spending across the world.

Several major pharma and biotech companies are developing therapies for Type 2 Diabetes. Currently, Lexicon Pharmaceuticals is leading the therapeutics market with its Postoperative Pain drug candidates in the most advanced stage of clinical development.

Type 2 Diabetes Companies in the Therapeutics Market Include:

AbbVie, ACADIA Pharmaceuticals, Adocia, Arthritis Innovation Corporation, Astellas Pharma, AstraZeneca, Bristol Myers Suibb, Cytogel, Daiichi Sankyo Company, Eli Lily and Company, Flexion Therapeutics, Forest Laboratories, Halozyme Therapeutics, Hanmi Pharmaceuticals, IItoo Pharma, Integrium, Jiangsu Hengrui Medicine, KeyBioscience AG, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Medspace Inc., Merck Sharp & Dohme Corp., Mylan, Nordic Bioscience A/S, Novartis, Novo Nordisk, Noxxon Pharma AG, Oramed Ltd., Oramed Pharmaceuticals, Pfizer, Phenomix, Saniona, Sanofi, and many others.

Type 2 Diabetes Therapies Covered in the Report Include:

• Sotagliflozin: Lexicon Pharmaceuticals

• ORMD0801: Oramed Pharmaceuticals

• Tirzepatide /LY3298176: Eli Lilly and Company

• HM12460A: Hanmi Pharmaceuticals

• HM14220:Hanmi Pharmaceuticals

• Danuglipron: Pfizer

And Many More

Learn More About the Emerging Therapies & Key Companies in the Type 2 Diabetes Therapeutics Market @ 

https://www.delveinsight.com/sample-request/type-2-diabetes-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Type 2 Diabetes Competitive Intelligence Analysis

4. Type 2 Diabetes Market Overview at a Glance

5. Type 2 Diabetes Background and Overview

6. Type 2 Diabetes Patient Journey

7. Type 2 Diabetes Epidemiology and Patient Population

8. Type 2 Diabetes Treatment Algorithm, Current Treatment, and Medical Practices

9. Type 2 Diabetes Unmet Needs

10. Key Endpoints of Type 2 Diabetes Treatment

11. Type 2 Diabetes Marketed Products

12. Type 2 Diabetes Emerging Therapies

13. Type 2 Diabetes Seven Major Market Analysis

14. Attribute Analysis

15. Type 2 Diabetes Market Outlook (7 major markets)

16. Type 2 Diabetes Access and Reimbursement Overview

17. KOL Views on the Type 2 Diabetes Market.

18. Type 2 Diabetes Market Drivers

19. Type 2 Diabetes Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/type-2-diabetes-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight 

Structural Heart Devices Market

The global Structural Heart Devices market was valued at USD 9.81 billion in 2022, growing at a CAGR of 11.33% during the forecast period from 2023 to 2028; it is expected to reach USD 18.67 billion by 2028. The demand for Structural Heart Devices is primarily being boosted by the rapid growth in the prevalence of structural heart diseases, the growing popularity of minimally invasive interventions, the increase in the research and development activities in product development, and the approval of new and advanced products in the market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/